Search Results - Gregory D. Huhn

  • Showing 1 - 3 results of 3
Refine Results
  1. 1

    Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alaf... by Gregory D. Huhn, Aimee Wilkin, Cristina Mussini, Christoph D. Spinner, John Jezorwski, Mohsine El Ghazi, Erika Van Landuyt, Erkki Lathouwers, Kimberley Brown, Bryan Baugh, on behalf of the AMBER and EMERALD study groups

    Published in HIV Research & Clinical Practice (2021-02-01)
    Get full text
    Article


  2. 2

    Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study by Gregory D. Huhn, Joseph J. Eron, Pierre-Marie Girard, Chloe Orkin, Jean-Michel Molina, Edwin DeJesus, Romana Petrovic, Donghan Luo, Erika Van Landuyt, Erkki Lathouwers, Richard E. Nettles, Kimberley Brown, Eric Y. Wong

    Published in AIDS Research and Therapy (2019-08-01)
    Get full text
    Article


  3. 3

    HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens. by Gregory D Huhn, Moti Ramgopal, Mamta K Jain, Federico Hinestrosa, David M Asmuth, Jihad Slim, Deborah Goldstein, Shauna Applin, Julie H Ryu, Shuping Jiang, Stephanie Cox, Moupali Das, Thai Nguyen-Cleary, David Piontkowsky, Bill Guyer, Lorenzo Rossaro, Richard H Haubrich

    Published in PLoS ONE (2020-01-01)
    Get full text
    Article


Search Tools: